Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study.

Author: AcutoGiancarlo, AllaisGianni, AllaisRita, BenedettoChiara, BussoneGennaro, D'AndreaGiovanni, GrazziLicia, ManzoniGian Camillo, MoschianoFranca, ValguarneraFabio, d'OnofrioFlorindo

Paper Details 
Original Abstract of the Article :
Menstrually related migraine (MRM) affects more than half of female migraineurs. Because such migraines are often predictable, they provide a suitable target for treatment in the mild pain phase. The present study was designed to provide prospective data on the efficacy of almotriptan for treatment ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057443/

データ提供:米国国立医学図書館(NLM)

Almotriptan: A Potential Solution for Menstrually Related Migraine

Migraine, a debilitating headache disorder, can be particularly challenging for women, often occurring in conjunction with their menstrual cycle. This study investigates the effectiveness of almotriptan, a triptan medication, in treating menstrually related migraine (MRM).

Researchers, like skilled desert navigators predicting the course of a sandstorm, aimed to understand how almotriptan affects MRM. Their findings suggest that almotriptan, administered early in the migraine cycle, can effectively reduce pain and improve the quality of life for women with MRM.

A Promising Treatment for Menstrually Related Migraine

The study provides evidence that almotriptan can be an effective treatment for MRM, offering relief to women who experience debilitating migraines during their menstrual cycle.

Hope for Managing Migraine Pain

This study offers hope for women struggling with MRM. Almotriptan, when administered early in the migraine cycle, may provide relief from pain and improve the quality of life for women suffering from this debilitating condition.

Dr.Camel's Conclusion

This study sheds light on the potential of almotriptan as a treatment for MRM. It's like finding a hidden oasis in the vast desert of migraine research, offering relief for women experiencing this challenging condition. This research underscores the importance of seeking early treatment for migraine and exploring options like almotriptan to improve patient outcomes.

Date :
  1. Date Completed 2011-04-28
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20660540

DOI: Digital Object Identifier

PMC3057443

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.